Phase I Single-blind Clinical Trial to Evaluate the Safety and Local Immune Activation of a Toll-like Receptor 5 Agonist (FLAMOD) Administered by Aerosol

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Pneumonia

Interventions

DRUG

FLAMOD

FLAMOD (GMP-grade flagellin) inhalation

DRUG

Placebo

Placebo inhalation

Trial Locations (1)

RECRUITING

Centre hospitalier régional universitaire de de Tours, Tours

All Listed Sponsors

collaborator

European Union

OTHER

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV